News from oncogenex pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 30, 2015, 16:00 ET

OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its second quarter 2015 financial results on Thursday,...

Jul 13, 2015, 07:00 ET

OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or...

Jun 10, 2015, 07:00 ET

FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's...

Jun 01, 2015, 10:45 ET

OncoGenex Announces Data from Borealis-1™ Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that results from an exploratory analysis of the Phase 2  Borealis-1™ trial...

May 30, 2015, 14:15 ET

OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a...

May 20, 2015, 16:00 ET

OncoGenex Announces Data to be Presented at ASCO 2015 Annual Meeting

Survival Benefit Seen with Custirsen and Apatorsen in Patients with Greatest Therapeutic Need  OncoGenex Pharmaceuticals, Inc. (NASDAQ:...

May 14, 2015, 16:01 ET

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2015

Conference call to be held on Thursday, May 14, 2015 at 4:30 p.m. Eastern Time OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced...

May 04, 2015, 16:01 ET

OncoGenex to Report First Quarter 2015 Financial Results on May 14, 2015

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2015 financial results on Thursday, May...

Apr 30, 2015, 08:37 ET

OncoGenex Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC

Funds to Help Further Development of Recently Re-acquired Custirsen Program  OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today...

Apr 30, 2015, 07:00 ET

OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update

Protocol Amended to Provide Faster Assessment of Survival Outcomes with Reduced Trial Size  OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI)...

Apr 27, 2015, 06:30 ET

OncoGenex Regains Rights to Custirsen from Teva

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a...

Apr 09, 2015, 06:30 ET

OncoGenex Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a...

Mar 26, 2015, 16:01 ET

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014

Conference call to be held on Thursday, March 26, 2015 at 4:30 p.m. Eastern Time  OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today...

Mar 23, 2015, 06:30 ET

OncoGenex to Report Financial Results for Fourth Quarter and Year End 2014 on March 26, 2015

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and year end 2014 financial results will be...

Feb 24, 2015, 09:00 ET
Feb 12, 2015, 17:45 ET

OncoGenex Announces Relocation of Corporate Headquarters, Expected to Yield Savings of at Least $4 Million Over Next Three Years

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed new lease agreements enabling the relocation of its...

Jan 16, 2015, 06:30 ET

OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis  OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI)...

Dec 30, 2014, 07:00 ET

OncoGenex to Regain Rights to Custirsen from Teva

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed an initial agreement with Teva Pharmaceutical Industries...

Dec 19, 2014, 08:00 ET

OncoGenex Announces Results from the Phase 2 Borealis-1™ Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer

Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in...

Dec 16, 2014, 06:30 ET

OncoGenex Announces Completion of Patient Enrollment in the Rainier™ Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Rainier™ clinical...